Last Updated: August 9, 2026

Details for Patent: 9,732,075


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,732,075 protect, and when does it expire?

Patent 9,732,075 protects QUVIVIQ and is included in one NDA.

This patent has fifty-one patent family members in thirty-four countries.

Summary for Patent: 9,732,075
Title:Benzimidazole-proline derivatives
Abstract:The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
Inventor(s):Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
Assignee: Idorsia Pharmaceuticals Ltd
Application Number:US14/405,649
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,732,075

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Idorsia QUVIVIQ daridorexant hydrochloride TABLET;ORAL 214985-001 Apr 7, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF INSOMNIA ⤷  Start Trial
Idorsia QUVIVIQ daridorexant hydrochloride TABLET;ORAL 214985-002 Apr 7, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF INSOMNIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,732,075

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
12170748Jun 4, 2012
13158520Mar 11, 2013
PCT Information
PCT FiledJune 03, 2013PCT Application Number:PCT/IB2013/054567
PCT Publication Date:December 12, 2013PCT Publication Number: WO2013/182972

International Family Members for US Patent 9,732,075

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2855453 ⤷  Start Trial PA2022518 Lithuania ⤷  Start Trial
European Patent Office 2855453 ⤷  Start Trial 301197 Netherlands ⤷  Start Trial
European Patent Office 2855453 ⤷  Start Trial 2022C/543 Belgium ⤷  Start Trial
European Patent Office 2855453 ⤷  Start Trial 122022000059 Germany ⤷  Start Trial
European Patent Office 2855453 ⤷  Start Trial LUC00279 Luxembourg ⤷  Start Trial
European Patent Office 2855453 ⤷  Start Trial CA 2022 00041 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.